Effect of combined dexamethasone/lenalidomide therapy on NK cell-receptor levels in myeloma patients.

C. Carter,S. Feyler,N. Smalle,G. Scott,C. Parrish,K. Cullen,C. Kallmeyer,P. Wood,G. Cook
DOI: https://doi.org/10.1182/blood-2011-08-372680
IF: 20.3
2011-12-08
Blood
Abstract:To the editor: We read with interest the recent article by Hsu et al[1][1] that reported that the immunomodulatory properties of lenalidomide were lost when used in combination with dexamethasone in multiple myeloma patients. Specifically, they reported reduced natural killer (NK) activity caused
What problem does this paper attempt to address?